Literature DB >> 28987599

Anti-sepsis protection of Xuebijing injection is mediated by differential regulation of pro- and anti-inflammatory Th17 and T regulatory cells in a murine model of polymicrobial sepsis.

Xi Chen1, Yuxin Feng1, Xiya Shen2, Guixiang Pan1, Guanwei Fan3, Xiumei Gao3, Jihong Han4, Yan Zhu5.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Xuebijing injection (XBJ), a Chinese herbal medicine containing extracts from 5 herbs, is frequently used as an add-on with standard therapies to treat sepsis or septic shock with fewer side effects in China. Nonetheless, its mechanism of action on septic shock remains to be unveiled. We explored the differential effects of XBJ on subtypes of CD4+ T cell differentiation and septic shock protection in a murine model to understand the contribution of XBJ to regulation of the inflammation-immune axis function.
MATERIALS AND METHODS: In vitro T cell differentiation assays were performed to determine the effect of XBJ on CD4+ regulatory T cell and T helper cell differentiation. Besides, 2ml/kg, 6ml/kg- and 18ml/kg of XBJ were administered to different groups of septic mice once/day for 5 days after cecal ligation and puncture (CLP) surgeries. 36h after CLP, serum levels of pro-inflammatory cytokine TNF-α and IL-6 were determined with Elisa. Frequencies of CD4+ T cells were analyzed after staining with Tregs and T helper cell lineage specific antibodies by flow cytometer.
RESULTS: XBJ at 18ml/kg stimulated Treg differentiation and moderately inhibited Th17 differentiation in vitro. Accordingly, 18ml/kg XBJ facilitated the expansion of IL-10+ Tregs and normalized pro-inflammatory Th17 population in septic mice. This regimen also significantly reduced serum levels of inflammatory cytokines TNF-α and IL-6 in septic mice. Additionally, 18ml/kg XBJ injection effectively prevented neutrophil infiltration into the lung and kidney and improved survival in this septic shock model.
CONCLUSIONS: In summary, XBJ improves survival in septic shock partially through preventing cytokine storm, inhibiting inflammation and regulating the balance of Tregs and Th17 cells. Thus, higher dose of XBJ is a potential regimen to benefit septic shock patients.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CLP; Inflammation; Polymicrobial sepsis; Sepsis; Septic shock; T cell; Xuebijing injection

Mesh:

Substances:

Year:  2017        PMID: 28987599     DOI: 10.1016/j.jep.2017.10.001

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  29 in total

1.  COVID-19 managed with early non-invasive ventilation and a bundle pharmacotherapy: A case report.

Authors:  Mian Peng; Di Ren; Xue-Yan Liu; Jin-Xiu Li; Rong-Lin Chen; Bao-Jun Yu; Yong-Feng Liu; Xi Meng; Yan-Si Lyu
Journal:  World J Clin Cases       Date:  2020-05-06       Impact factor: 1.337

2.  A real-world study on adverse drug reactions to Xuebijing injection: hospital intensive monitoring based on 93 hospitals (31,913 cases).

Authors:  Rui Zheng; Hui Wang; Zhi Liu; Xiaohui Wang; Jing Li; Xiang Lei; Yilin Fan; Si Liu; Zhiqiao Feng; Hongcai Shang
Journal:  Ann Transl Med       Date:  2019-03

3.  Paeoniflorin and Hydroxysafflor Yellow A in Xuebijing Injection Attenuate Sepsis-Induced Cardiac Dysfunction and Inhibit Proinflammatory Cytokine Production.

Authors:  Xin-Tong Wang; Zhen Peng; Ying-Ying An; Ting Shang; Guangxu Xiao; Shuang He; Xi Chen; Han Zhang; Yuefei Wang; Tao Wang; Jun-Hua Zhang; Xiumei Gao; Yan Zhu; Yuxin Feng
Journal:  Front Pharmacol       Date:  2021-04-13       Impact factor: 5.810

4.  Protecting Intestinal Microenvironment Alleviates Acute Graft-Versus-Host Disease.

Authors:  Zhengcan Zhou; Ting Shang; Xiurong Li; Hongyan Zhu; Yu-Bo Qi; Xin Zhao; Xi Chen; Zhe-Xin Shi; Guixiang Pan; Yue-Fei Wang; Guanwei Fan; Xiumei Gao; Yan Zhu; Yuxin Feng
Journal:  Front Physiol       Date:  2021-02-12       Impact factor: 4.566

Review 5.  Xuebijing Injection Combined with Antibiotics for the Treatment of Spontaneous Bacterial Peritonitis in Liver Cirrhosis: A Meta-Analysis.

Authors:  Dan Han; Ran Wang; Yang Yu; Mingyu Sun; Rolf Teschke; Fernando Gomes Romeiro; Andrea Mancuso; Tingxue Song; Zhong Peng; Bing Han; Xinmiao Zhou; Wenchun Bao; Qianqian Li; Kexin Zheng; Yingying Li; Zhaohui Bai; Xiaozhong Guo; Xingshun Qi
Journal:  Evid Based Complement Alternat Med       Date:  2018-03-19       Impact factor: 2.629

6.  Antiseptic Activity of Ethnomedicinal Xuebijing Revealed by the Metabolomics Analysis Using UHPLC-Q-Orbitrap HRMS.

Authors:  Lihua Zuo; Lin Zhou; Tanye Xu; Zhuolun Li; Liwei Liu; Yingying Shi; Jian Kang; Guanmin Gao; Shuzhang Du; Zhi Sun; Xiaojian Zhang
Journal:  Front Pharmacol       Date:  2018-03-29       Impact factor: 5.810

Review 7.  Combating the Coronavirus Pandemic: Early Detection, Medical Treatment, and a Concerted Effort by the Global Community.

Authors:  Zichao Luo; Melgious Jin Yan Ang; Siew Yin Chan; Zhigao Yi; Yi Yiing Goh; Shuangqian Yan; Jun Tao; Kai Liu; Xiaosong Li; Hongjie Zhang; Wei Huang; Xiaogang Liu
Journal:  Research (Wash D C)       Date:  2020-06-16

8.  Response of regulatory T cells to classic heat stroke in mice.

Authors:  Jie Hu; Hong-Jun Kang; Chao Liu; Pan Hu; Meng-Meng Yang; Fei-Hu Zhou
Journal:  Exp Ther Med       Date:  2018-09-19       Impact factor: 2.447

9.  XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial.

Authors:  Yuanlin Song; Chen Yao; Yongming Yao; Hui Han; Xiaodong Zhao; Kaijiang Yu; Luyi Liu; Ying Xu; Zhongmin Liu; Qingshan Zhou; Ying Wang; Zhuang Ma; Youguang Zheng; Dawei Wu; Zhongzhi Tang; Minzhou Zhang; Shuming Pan; Yanfen Chai; Yan Song; Jian Zhang; Lei Pan; Yi Liu; He Yu; Xuezhong Yu; Hong Zhang; Xiaoge Wang; Zhaohui Du; Xianyao Wan; Yijun Tang; Yingping Tian; Yimin Zhu; Hongliang Wang; Xiaoyan Yan; Zhi Liu; Boli Zhang; Nanshan Zhong; Hongcai Shang; Chunxue Bai
Journal:  Crit Care Med       Date:  2019-09       Impact factor: 7.598

Review 10.  Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China.

Authors:  Wei Zhuang; Zheng Fan; Yanqi Chu; Haizheng Wang; Ying Yang; Li Wu; Nan Sun; Ge Sun; Yuqiao Shen; Xiaolan Lin; Guiming Guo; Shengyan Xi
Journal:  Front Pharmacol       Date:  2020-07-17       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.